Physician profile
Jonathan Gravlee
NPI 1245886837
$10,196.69
in general payments reported to CMS, 2019-2025
23 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $457 · 2020: $330 · 2021: $1,171 · 2022: $1,576 · 2023: $2,201 · 2024: $2,283 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,661.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,400.06 | 2019-2025 | Precision7, Eysuvis, Precision 1 |
| Coopervision INC. | $1,366.39 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $1,024.53 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $991.54 | 2022-2025 | Infuse, Xiidra, Miebo |
| Abbvie INC. | $835.55 | 2022-2025 | |
| Oyster Point Pharma, INC. | $598.28 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $485.38 | 2022-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $449.43 | 2020-2021 | |
| Biotissue Holdings INC. | $329.94 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $279.53 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $252.37 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $234.65 | 2021-2023 | |
| Harrow Eye, LLC | $209.82 | 2024-2025 | Vevye, Natacyn, Tobradex St |
| Eyevance Pharmaceuticals LLC | $161.34 | 2022 | |
| Allergan, INC. | $154.26 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.84 | 2025 | Izervay |
| Glaukos Corporation | $102.72 | 2023 | |
| Kala Pharmaceuticals, INC. | $61.11 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $55.67 | 2022 | |
| Sight Sciences, INC. | $24.21 | 2023 | Tearcare System |
| Thea Pharma INC. | $23.21 | 2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $19.15 | 2021 | |
| Mallinckrodt Hospital Products INC. | $15.71 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gravlee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.